Philippe Camus, M.D.

Dijon, France

Back to drug

The Drug-Induced Respiratory Disease Website

XXXIX.e

Rechallenge may not lead to relapse of the AE/ILD

Publications

Bickert C, Kahnert K, Kauffmann-Guerrero D, Götschke J, Syunyaeva Z, Behr J, Tufman A

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies.

Therapeutic advances in medical oncology 2021;13;17588359211018028 — 2021 — 17588359211018028

Mohammed T, Mangeshkar S, Rathmann J

Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis.

Case reports in oncology 2021 May-Aug;14;733-738 — 2021 May-Aug — 733-738

Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T

Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.

Investigational new drugs 2021 04;39;571-577 — 2021 04 — 571-577